Bispecific antibodies are redefining what’s possible in multiple myeloma treatment, but they with immune-related risks.
Unlike traditional chemotherapy, which broadly targets rapidly dividing cells, bispecific antibodies are designed to work as T-cell engagers (TCEs) by bringing myeloma cells and your immune system’s T cells into closer contact. That precision sets them apart from both chemotherapy and CAR T-cell therapy for myeloma, which requires complex ex vivo cell manufacturing before infusion. Researchers and clinicians are exploring ways to make bispecific antibody administration more convenient, and some centers are evaluating outpatient protocols as an option. Ask your care team whether outpatient administration might be suitable for you.
That shift, however, doesn’t reduce complexity. Determining who faces the greatest risk remains critical. Some healthcare teams may use a threshold approach to help identify patients who may need closer monitoring or more intensive management during bispecific antibody treatment. Hospital monitoring for cytokine release syndrome (CRS) and the possible use of tocilizumab for CRS management are approaches your care team may consider as part of safe BsAb treatment. Understanding those immune challenges, starting with cytokine release syndrome, is where any responsible clinical conversation must begin.
Cytokine release syndrome (CRS). Understanding the immune surge
CRS is believed to be a systemic inflammatory response that may occur when bispecific antibodies activate T-cells, potentially leading to the release of immune signaling proteins called cytokines into the bloodstream. CRS may occur early in treatment, including during the first few doses or step-up phases of therapy, though timing can vary from patient to patient. Making early monitoring especially critical for bispecific antibody safety in myeloma.
Step-up dosing and prophylactic strategies
Step-up dosing is one approach that your care team may use to help manage the risk of severe side effects. Ask your doctor whether this strategy might be appropriate for you. Rather than initiating therapy at full therapeutic levels, care teams gradually escalate doses over several days, an approach intended to help the immune system adjust and may reduce the intensity of early cytokine surges. Corticosteroids and adequate hydration are commonly used alongside bispecific antibody therapy and may help manage initial immune activation, though your care team can discuss how these measures apply to your specific situation. Tocilizumab, an IL-6 receptor antagonist, plays a dual role here. Used both proactively and reactively depending on the patient’s risk profile and how early symptoms emerge. Together, these layered interventions don’t eliminate immune responses entirely, they shape them into something manageable. But as acute CRS becomes more controllable, a different and slower-moving risk begins to demand equal attention.
Why infection risk may outweigh CRS concerns
When you look beyond acute CRS, the broader picture of myeloma bispecific antibody side effects tells a more sobering story, one where long-term infectious complications emerge as the dominant driver of patient morbidity.
CRS commands attention because it’s visible and immediate. But the deeper, slower threat is immune collapse. BCMA-targeted therapies don’t just activate T-cells, they deplete normal plasma cells alongside malignant ones, producing a state of prolonged B-cell aplasia that leaves patients without the antibody-producing machinery they need to fight off infection. B-cell aplasia from BCMA-targeted therapies may persist while treatment is ongoing, and your care team can discuss what to expect during and after your course of therapy.
The contrast with non-BCMA agents is meaningful. Talquetamab targets GPRC5D instead of BCMA, and early experience suggests it may have a different toxicity profile compared to BCMA-targeting bispecific antibodies. Your care team can discuss what is currently known about its potential side effects, including effects on B cells and mucosal or skin concerns. Neither is categorically safer, they simply demand different long-term management strategies from the care team.
Most common infections in multiple myeloma patients
Respiratory tract infections, particularly pneumonia and sinusitis, have been observed in patients treated with bispecific antibodies, and your care team can discuss whether these are a concern for your individual situation. The same B-cell depletion that drives CRS in myeloma treatment also strips away the antibody defenses that normally intercept bacterial and viral invaders at mucosal surfaces.
Viral reactivation compounds this risk significantly. Because bispecific antibody therapy affects immune function, patients and their care team should be aware that dormant infections like varicella-zoster virus (shingles) or Hepatitis B may potentially reactivate. Your doctor can discuss whether monitoring or preventive measures may be appropriate for you. Treatment-emergent cytopenias, particularly neutropenia, may lower the body’s ability to fight bacterial infections during bispecific antibody therapy. Your care team can monitor your blood counts and discuss what signs of infection to watch for. Understanding which infections pose the greatest threat sets the stage for addressing one of the most consequential, and underrecognized, drivers of that vulnerability. The depletion of protective antibodies itself.
Hypogammaglobulinemia and antibody replacement
Hypogammaglobulinemia, or sustained depletion of protective IgG antibodies, may contribute to infection risk in some patients receiving bispecific antibodies. Your care team can help determine whether this is a factor in your individual infection risk. Hypogammaglobulinemia, or low levels of antibodies, is a commonly observed effect that may occur during BCMA bispecific antibodies therapy and is something your care team will monitor.
BCMA-targeting agents work by affecting plasma cells, which play a role in producing immunoglobulins that help defend against bacterial and viral pathogens. This effect on plasma cells may contribute to increased infection risk in some patients, which is why your care team will monitor you closely during treatment. Some care teams may consider IVIG replacement therapy when IgG levels fall below certain thresholds, though the specific level and timing can vary based on individual patient factors. Ask your care team whether IVIG might be appropriate for you if your immunoglobulin levels drop during treatment. Vaccine response may be reduced during active bispecific antibody treatment, and your care team can advise whether vaccination timing or strategy should be adjusted based on your individual treatment plan. Understanding how hypogammaglobulinemia compounds vulnerability sets essential context for the structured clinical protocols, grading systems, monitoring criteria, and red-flag checklists addressed next.
Clinical protocols for adverse event management
Structured clinical protocols, not reactive improvisation, are what separate manageable bispecific antibody toxicity in myeloma from outcomes that spiral quickly out of control.
Doctors use a grading framework for CRS that ranges from Grade 1 through Grade 4, and your care team may adjust your treatment plan based on the grade you experience. Fever is often considered an early sign of CRS, while more severe grades may involve oxygen requirements, blood pressure changes, or organ stress. Your care team can explain how CRS symptoms are graded and what to watch for.
Beyond CRS, ICANS (immune effector cell-associated neurotoxicity syndrome) and CRS are distinct conditions, and your care team may monitor them through separate assessment approaches during bispecific antibody treatment.
Care teams may use structured cognitive checks and handwriting tests as part of monitoring for early neurological changes in ICANS. Ask your care team what specific assessments they use to watch for neurological symptoms. GPRC5D bispecific antibodies may have different neurotoxicity patterns compared to BCMA-targeting agents, so your care team will monitor you accordingly.
A practical red-flag checklist helps patients and caregivers act fast. Symptoms warranting immediate contact with the care team include:
- Your care team may want you to report fever above 100.4°F (38°C) during treatment. Ask your doctor what specific symptoms or temperature readings should prompt you to reach out.
- Some neurological changes, such as confusion, slurred speech, or difficulty writing, may warrant a prompt call to your care team to rule out serious side effects.
- Symptoms such as severe chills, rigors, or rapid breathing may warrant contact with your care team, particularly if they develop or worsen quickly. Ask your care team which symptoms should prompt immediate outreach.
- Low blood pressure or signs that your blood pressure may be dropping are symptoms you should discuss with your care team, as they can be associated with CRS and may need prompt attention.
One honest caveat. The monitoring burden itself is a real disadvantage of bispecific therapy. Frequent clinic visits, laboratory draws, and observation periods place significant logistical and emotional challenges on patients, particularly those without strong support networks.
Neurotoxicity (ICANS) monitoring protocols
While CRS symptoms in myeloma, fever, hypotension, and chills, are relatively well-recognized, immune effector cell-associated neurotoxicity syndrome (ICANS) can look entirely different and, without a structured monitoring protocol, is easy to miss.
ICANS may present with neurological symptoms such as confusion, word-finding difficulty, aphasia, or difficulty writing. If you experience any of these symptoms during treatment, contact your care team right away. Healthcare providers may use cognitive assessment tools to help monitor for ICANS (immune effector cell-associated neurotoxicity syndrome) severity during treatment with bispecific antibodies. Your care team can explain what assessments they use and how often they will check for any cognitive changes. For high-risk ICANS patients, your care team may consider seizure prophylaxis and EEG monitoring as part of your management plan. And unlike bispecific antibodies infection prophylaxis, which operates on a continuous preventive timeline, ICANS management is acutely responsive, acting fast on early neurological signals is what limits escalation.
Patient education and home monitoring
Bispecific antibodies monitoring doesn’t end at the clinic door. What patients and caregivers observe between visits is often what catches a problem early enough to act on.
Your care team will typically provide a home toolkit: a reliable thermometer, a blood pressure cuff, and a symptom logbook. Difficulty breathing can be a sign of a serious reaction during bispecific antibody therapy, so contact your care team right away if you notice any new breathing problems. A sustained drop in blood pressure is a symptom you should report to your care team during bispecific antibody therapy, as they can help determine whether it needs prompt attention. Caregiver training matters here too. Cognitive changes such as confusion or word-finding difficulty have been reported in some patients with ICANS and may be worth discussing with your care team if they occur. And for patients receiving IVIg for bispecific antibodies therapy, logging any new symptoms around infusion days helps your team identify patterns that routine lab work alone might not catch.
Key takeaways: navigating bispecific antibody therapy
Bispecific antibody therapy for multiple myeloma demands two distinct kinds of vigilance, one acute, one sustained.
Unlike traditional chemotherapy for multiple myeloma, bispecifics spare patients from broad cellular damage while introducing a distinct immune vulnerability profile that persists well beyond active infusion cycles. Your care team is the central anchor here, monitoring neurotoxicity signals, adjusting prophylaxis schedules, and catching the subtle changes that home monitoring logs help surface between visits.
In 2026, myeloma care is defined by a single balancing act: achieving deep, durable responses while protecting the quality of life that makes those responses meaningful. Connect with your care team to build a personalized care plan grounded in the evidence, because informed patients, supported by prepared care teams, are the ones who navigate this therapy most successfully.
Disclaimer: The information provided in this article is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Outcomes4Me is not acting as your caregiver, and any suggestions or guidance offered should not replace the advice of your healthcare provider or qualified medical professional. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding a medical condition.
